PERCORTEN by Novartis is clinical pharmacology: desoxycorticosterone pivalate (docp), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. First approved in 1942.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
PERCORTEN (desoxycorticosterone pivalate, DOCP) is a long-acting mineralocorticoid ester administered as an intramuscular microcrystalline depot pellet. It treats hypoadrenocorticism by mimicking aldosterone's effects, increasing renal sodium and water retention to restore blood volume and prevent hypotensive shock. The drug works by binding cytoplasmic receptor proteins that translocate to the nucleus and modulate genetic transcription of sodium-regulating proteins.
Product approaching loss of exclusivity with minimal competitive pressure (30%), suggesting focused commercial team supporting a mature, niche veterinary franchise.
CLINICAL PHARMACOLOGY: Desoxycorticosterone pivalate (DOCP), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. It reacts with receptor proteins in the cytoplasm to form a steroid-receptor complex. This complex moves into the nucleus, where it…
Worked on PERCORTEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PERCORTEN offers deep expertise in a specialized veterinary therapeutic area with a mature, stable patient population and established clinical protocols. The role emphasizes stakeholder retention, physician relationship management, and defending market position against emerging competition rather than growth-oriented innovation.